FibroGen Inc (NASDAQ:FGEN) CEO Thomas B. Neff sold 48,180 shares of the company’s stock in a transaction dated Friday, February 8th. The stock was sold at an average price of $56.47, for a total transaction of $2,720,724.60. Following the completion of the sale, the chief executive officer now directly owns 2,680,346 shares of the company’s stock, valued at $151,359,138.62. The sale was disclosed in a filing with the SEC, which is accessible through this link.

FibroGen stock opened at $56.98 on Monday. FibroGen Inc has a twelve month low of $37.27 and a twelve month high of $68.55. The company has a market cap of $4.84 billion, a PE ratio of -32.94 and a beta of 1.77. The company has a quick ratio of 6.76, a current ratio of 6.76 and a debt-to-equity ratio of 0.20.

FibroGen (NASDAQ:FGEN) last released its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.15). FibroGen had a negative net margin of 87.84% and a negative return on equity of 24.59%. The company had revenue of $29.00 million for the quarter, compared to the consensus estimate of $36.48 million. FibroGen’s quarterly revenue was down 28.6% on a year-over-year basis. On average, equities analysts expect that FibroGen Inc will post -1.55 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. grew its position in shares of FibroGen by 622.4% during the 4th quarter. Meeder Asset Management Inc. now owns 614 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 529 shares during the period. Intercontinental Wealth Advisors LLC bought a new position in shares of FibroGen during the 4th quarter valued at approximately $37,000. Bank of Montreal Can grew its position in shares of FibroGen by 177.3% during the 4th quarter. Bank of Montreal Can now owns 1,722 shares of the biopharmaceutical company’s stock valued at $80,000 after acquiring an additional 1,101 shares during the period. Trexquant Investment LP bought a new position in shares of FibroGen during the 3rd quarter valued at approximately $201,000. Finally, Pacer Advisors Inc. bought a new position in shares of FibroGen during the 3rd quarter valued at approximately $246,000. 64.61% of the stock is owned by hedge funds and other institutional investors.

A number of equities research analysts have issued reports on FGEN shares. Leerink Swann set a $84.00 price objective on shares of FibroGen and gave the stock a “buy” rating in a research report on Monday, October 15th. BidaskClub raised shares of FibroGen from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 10th. Zacks Investment Research downgraded shares of FibroGen from a “buy” rating to a “hold” rating in a research report on Tuesday, November 13th. Mizuho reaffirmed a “buy” rating and issued a $74.00 price objective on shares of FibroGen in a research report on Monday, December 17th. Finally, TheStreet downgraded shares of FibroGen from a “c-” rating to a “d+” rating in a research report on Wednesday, November 21st. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $70.25.

TRADEMARK VIOLATION WARNING: “FibroGen Inc (FGEN) CEO Sells $2,720,724.60 in Stock” was originally published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2019/02/11/fibrogen-inc-fgen-ceo-sells-2720724-60-in-stock.html.

About FibroGen

FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.

Featured Story: Net Margin

Insider Buying and Selling by Quarter for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.